Elsevier

IMUNON Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Transfer, Ovarian cancer, Immunotherapy, Patient, Lung, Vaccine, Good manufacturing practice, Sale, CMC, IND, Bangladesh Technical Education Board, IPR, Investment, Clinical trial, Neoplasm, Research, Primate, DNA, NOL, MD Anderson Cancer Center, Trial of the century, ITT, Safety, MRD, Interim, Silicon Valley Bank, Vaccination, Food, CMOS, Elsevier, CD8, Drug discovery, SVB, CRS, University, Death, SARS-CoV-2, Earnings call, Lassa mammarenavirus, PFS, Immunoglobulin G, FDA, OS, CD4, Temperature, Progression-free survival, COVID-19, Mouse, Messenger, Human, Wistar Institute, Hospital

LAWRENCEVILLE, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of first-line, locally advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic DNA plasmid and a synthetic DNA delivery technology for the expression of pathogen antigens in preclinical studies for the development of next-generation vaccines.

Key Points: 
  • “We remain on track to report topline results mid-year from the OVATION 2 Study with IMNN-001 in advanced ovarian cancer.
  • In September 2023, the Company announced interim PFS and OS data with IMNN-001 in its OVATION 2 Study.
  • The Company is hosting a conference call to provide a business update, discuss 2023 financial results and answer questions at 10:00 a.m. Eastern time today.
  • To participate in the call, please dial 866-777-2509 (Toll-Free/North America) or 412-317-5413 (International/Toll) and ask for the IMUNON 2023 Earnings Call.

Study Evaluates Prevalence of Four Recommended Practices for Suicide Prevention Following Hospital Discharge

Retrieved on: 
Tuesday, March 12, 2024
Elsevier, Prevalence, Joint, Joint Commission, Health, The Pew Charitable Trusts, Risk, Nursing care plan, Patient, Hospital, NPSG, Death, ABPP, LMSW, Quality, MPH, Doctor of Psychology, Safety, Suicide, Pew, Patient safety, Nursing

A new study , funded by Pew Charitable Trusts, in The Joint Commission Journal on Quality and Patient Safety (JQPS), evaluated the prevalence of four suicide prevention activities following hospital discharge among Joint Commission-accredited hospitals:

Key Points: 
  • A new study , funded by Pew Charitable Trusts, in The Joint Commission Journal on Quality and Patient Safety (JQPS), evaluated the prevalence of four suicide prevention activities following hospital discharge among Joint Commission-accredited hospitals:
    While these specific suicide prevention activities are not explicitly required by The Joint Commission’s National Patient Safety Goal (NPSG), they are recommended by many suicide prevention experts.
  • By understanding the adoption of recommended practices for suicide prevention, hospitals can help improve care for people at risk and save lives.”
    Researchers calculated the percentage of hospitals reporting the implementation of these recommended discharge practices.
  • While hospitals typically implemented common (and low resource) discharge practices such as providing a list of crisis resources and making referrals, many of the recommended and more robust suicide prevention practices had not yet been widely implemented.
  • Very few hospitals (4%) met full criteria for implementing all four recommended suicide prevention activities at time of discharge.

BenevolentAI Appoints New Chief Technology Officer

Retrieved on: 
Wednesday, March 20, 2024
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Health Technology, Professional Services, Machine learning, EBI, Elsevier, Bioinformatics, Drug discovery, University of Edinburgh, Artificial intelligence, Benevolence, AI, Doctor of Philosophy, Engineering, BAI, Family, Euronext Amsterdam, European

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.
  • The Company is pleased to announce the appointment of Dr. James Malone as BenevolentAI’s new Chief Technology Officer.
  • As Chief Technology Officer at SciBite, James helped build software using ontologies, machine learning and knowledge graphs to analyse scientific data.
  • Specifically, his experience in building technology to support R&D within biotech will help with the continuing development of the BenevolentAI PlatformTM, which is critical for us to deliver cutting edge AI-driven drug discovery.”
    Dr. James Malone, incoming Chief Technology Officer, commented: “I’m excited to join the leadership team at BenevolentAI.

Deerfield Agency Welcomes Bill Veltre as EVP, Head of Media

Retrieved on: 
Wednesday, March 20, 2024
Elsevier, Patient, Digitas Health, PHM, Bristol Myers Squibb, Migraine, CMI, Allergan, WPP, Marketing, Pharmaceutical industry

CONSHOHOCKEN, Pa., March 20, 2024 /PRNewswire/ -- Deerfield Agency, one of the leading health marketing and communications firms for health companies, today announced Bill Veltre has joined as Executive Vice President, Head of Media.

Key Points: 
  • CONSHOHOCKEN, Pa., March 20, 2024 /PRNewswire/ -- Deerfield Agency, one of the leading health marketing and communications firms for health companies, today announced Bill Veltre has joined as Executive Vice President, Head of Media.
  • With nearly two decades of experience in healthcare marketing, Bill will direct paid media services for the agency, guiding further development of the company's strategic and analytical approach to media and digital strategy.
  • "Bill's appointment signifies an exciting milestone for Deerfield Agency as our media service offerings grow and we continue to enhance our media insights and reporting capabilities," said Frank Burrell, Managing Partner at Deerfield.
  • Bill is a seasoned healthcare marketing professional with expertise in the successful integration of media, creative, and analytics.

US monetary policy is more powerful in low economic growth regimes

Retrieved on: 
Tuesday, April 2, 2024
Tao, Research Papers in Economics, Excess, American Economic Journal, Doan, Policy, RT, Interpolation, Economic growth, Absorption, Business, E32, Low, Browning, European Economic Review, UST, NBER, Forecasting, Macroeconomics, European Economic Association, Journal of Monetary Economics, Journal of Applied Econometrics, TVAR, Oxford University Press, Time series, Economic Inquiry, Paper, Linearity, Joshua Angrist, Nobuhiro, Environment, Political economy, Journal of Financial Economics, Rated R, R2, Website, Emi, Energy economics, Probability, Medical classification, Eurozone, Sigismund, Quarterly Journal of Economics, Zero lower bound, History, Nature, Chapter, ZT, Journal of Political Economy, Bocconi University, OLS, Statistics, University of California, Irvine, PDF, Classification, ECB, XS, ITP, Impact, Estimation, DGP, Mark Thoma, Social science, Elsevier, JEL, Cambridge University Press, Real, M1, Research, Textbook, Private sector, FED, Credit, UTT, Literature, Federal Reserve, Knotek, Evelyn Regner, Table, European Central Bank, Chow, FRED, Monetary economics, Wald, Ben Bernanke, Premium, P500, BIS, EWMA, International Economic Review, Federal funds rate, Money, Treasury, C32, The Economic Journal, Federal Reserve Economic Data, Employment, Risk, FFR, Suggestion, FOMC, Monte Carlo method, Sigmoid, VAR, Database, Projection, Ascari, The Journal of Finance, Yield curve, United States Treasury security, Economy, Fed, Figure, NFCI, Financial economics, EXP, Freedom, Central bank, PCE, Monetary policy, American Economic Review, Exercise, Interest, Samuel, URR, Rigidity, Business cycle, XT, Landing slot, Chap, Daron Acemoglu, Markov, Blue chip, Kuttner, Response, Quarterly Journal, YT, Channel, GDP, Standard, Effect, Federal, Cost, Christian Social Union (UK), Journal of Econometrics, Comm, Mark Gertler, Use, Economic statistics, IW, Bank for International Settlements, Finance Secretary (India), UC, Bank, Reproduction, Section, News, Housing, Data, Food industry
Key Points: 

    Elsevier Health Launches ClinicalKey AI, the Most Advanced Gen AI-Powered Clinical Decision Support Tool for Clinicians

    Retrieved on: 
    Thursday, February 29, 2024
    Privacy, Doctor of Philosophy, AI, University of New Mexico, MD, Physician, Health, Booth, MBA, Cone Health, Conference, Synthetic media, Cecil Textbook of Medicine, University, HIPAA, Responsibility, Medicine, Pediatrics, Heart, Intuition, Machine learning, Elsevier, Literature, Research, Accuracy and precision, Partnership, Medical device

    New York, New York--(Newsfile Corp. - February 29, 2024) - Elsevier Health, a global leader in medical information and data analytics, today launched ClinicalKey AI, the first and most advanced clinical decision support tool to be introduced in the US that combines the latest and most trusted medical content with generative artificial intelligence (AI) to help clinicians at the point of care. ClinicalKey AI has been launched in partnership with OpenEvidence, a company specializing in AI for medicine.

    Key Points: 
    • ClinicalKey AI has been launched in partnership with OpenEvidence, a company specializing in AI for medicine.
    • Our work with Elsevier Health has allowed us to deliver a superior user experience, combining trusted medical content with advanced AI technology through ClinicalKey AI.
    • ClinicalKey AI is built and maintained to deliver the accuracy and relevance of insights that healthcare institutions and physicians expect from Elsevier Health.
    • Attendees at the upcoming HIMSS Conference (March 11-15) can experience an in-person demonstration of ClinicalKey AI by visiting Elsevier at Booth 3048.

    IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine

    Retrieved on: 
    Thursday, February 22, 2024
    SARS-CoV-2, Vaccine, FDA, Food, Manuscript, COVID-19, Drug discovery, Immunity, Elsevier, IND, DNA, Mouse

    LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an article titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer” by Subeena Sood, Majed M. Matar, et. Al. [https://doi.org.10.1016/j.vaccine.2024.01.065] has been published in the peer-reviewed journal Vaccine, by Elsevier. The article is available at https://authors.elsevier.com/sd/article/S0264-410X(24)00077-X.

    Key Points: 
    • [ https://doi.org.10.1016/j.vaccine.2024.01.065 ] has been published in the peer-reviewed journal Vaccine, by Elsevier.
    • The study described in the article used IMUNON’s proprietary formulation against the spike proteins from two SARS-CoV-2 variants, both alone and in combination.
    • DNA formulated with PlaCCine resulted in a DNA vaccine product that was stable for up to one year at 4°C.
    • Dr. Corinne Le Goff, president and chief executive officer of IMUNON, said, “The publication of this manuscript in the prestigious peer-reviewed journal Vaccine adds to the growing body of preclinical data confirming the efficacy and desirable features of our PlaCCine vaccine modality.

    PolyU launches Research Centre for Electric Vehicles advancing smart electric vehicle research to achieve carbon neutrality goals

    Retrieved on: 
    Wednesday, February 28, 2024
    Carbon, EVS, Electric vehicle, Research, Policy Research Centre, Qianhai, Education, The Sun, Hong Kong Polytechnic University, Electronic engineering, University, Government of Hong Kong, Electricity, The Conservation Fund, Renaissance, Public policy, CLP Group, Transport, Student, Digital technology, Forum, BYD, Humanities, International Electrotechnical Commission, Advanced technology, Development, Polytechnic, Environment, Nation, Innovation, Intelligence, HKSAR, Government, Hetao, Distinguishing, China Power International Development, Memorandum, Elsevier, Renewable energy

    The Research Centre aims to develop a cutting-edge research platform to address energy and technical challenges presented by modern electric vehicles.

    Key Points: 
    • The Research Centre aims to develop a cutting-edge research platform to address energy and technical challenges presented by modern electric vehicles.
    • Electric vehicles are not only a means of transportation, they will promote smart transportation, smart energy, smart networks, smart cities, and smart societies.
    • The Centre will focus on cutting-edge research on electric vehicles and the friendly interaction  between electric vehicles, power grids and 5G networks.
    • It has also recently secured a Public Policy Research Fund to study hydrogen fuel cell vehicle and electric vehicle related policies.

    PolyU launches Research Centre for Electric Vehicles advancing smart electric vehicle research to achieve carbon neutrality goals

    Retrieved on: 
    Wednesday, February 28, 2024
    Carbon, EVS, Electric vehicle, Research, Policy Research Centre, Qianhai, Education, The Sun, Hong Kong Polytechnic University, Electronic engineering, University, Government of Hong Kong, Electricity, The Conservation Fund, Renaissance, Public policy, CLP Group, Transport, Student, Digital technology, Forum, BYD, Humanities, International Electrotechnical Commission, Advanced technology, Development, Polytechnic, Environment, Nation, Innovation, Intelligence, HKSAR, Government, Hetao, Distinguishing, China Power International Development, Memorandum, Elsevier, Renewable energy

    The Research Centre aims to develop a cutting-edge research platform to address energy and technical challenges presented by modern electric vehicles.

    Key Points: 
    • The Research Centre aims to develop a cutting-edge research platform to address energy and technical challenges presented by modern electric vehicles.
    • Electric vehicles are not only a means of transportation, they will promote smart transportation, smart energy, smart networks, smart cities, and smart societies.
    • The Centre will focus on cutting-edge research on electric vehicles and the friendly interaction  between electric vehicles, power grids and 5G networks.
    • It has also recently secured a Public Policy Research Fund to study hydrogen fuel cell vehicle and electric vehicle related policies.

    Elsevier Launches Complete HeartX(TM), the World's First Heart Education Experience in Spatial Computing

    Retrieved on: 
    Monday, February 5, 2024
    Myocardial infarction, Elsevier, Completeness, Anatomy, Heart, 3D, System, Diagnosis, Pathology, Health education, Female, Learning, Osmosis

    Complete HeartX provides learners with a unique experience to learn about the heart through interactive 3D models, images and simulations on Apple Vision Pro

    Key Points: 
    • The tool unlocks an immersive and powerful experience that allows users to discover the heart like never before.
    • By being able to explore the heart in stunning detail, users can bridge the gap between theory and practice.
    • Complete HeartX combines detailed 3D models, animations, images, videos, educational scenes and clinical simulations to make learning about the heart engaging and informative.
    • Complete HeartX is only available on Apple Vision Pro and the experience options can be purchased from the Apple Vision Pro App Store.